{"name":"Larimar Therapeutics, Inc.","slug":"larimar-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for rare and underserved diseases. The company's lead candidate, CTI-1601, is currently in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":154224000,"netIncome":-165673000,"cash":85412000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CTI-1601","genericName":"CTI-1601","slug":"cti-1601","indication":"Amyotrophic lateral sclerosis (ALS)","status":"phase_2"}]}],"pipeline":[{"name":"CTI-1601","genericName":"CTI-1601","slug":"cti-1601","phase":"phase_2","mechanism":"CTI-1601 is a gene therapy that aims to restore motor neuron function in patients with amyotrophic lateral sclerosis (ALS).","indications":["Amyotrophic lateral sclerosis (ALS)"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNSVVnNVFsaXh6blpvbEIzbTZyQnlpSG41TTAyaXd1SllRdEF4ZGUxSC1PVU80STVGRjJrOXBBcXdTSXU0TU1pSzZsNnZJNmctNmstTG55RlVVbnBORmt3bVRzdkFUT21SbGxuUzZoYzBkX1lVTl9IMmdCdmlZWDdHOEU2M2JhRnlka3JaaFBDaVZjZ0VWbUp0ZVd0NlluZXc0WVlXMlU1U053LU1pS1RyVVRJRExUbkVabkRHVnB3?oc=5","date":"2026-03-06","type":"pipeline","source":"TradingView","summary":"LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - TradingView","headline":"LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-25","type":"regulatory","source":"simplywall.st","summary":"Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp - simplywall.st","headline":"Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQQmU4N2hWTlEwb1lUSHJfeXlnOFlDbkRyWUNyZWxPT29QX3Z0NUl0eTE4UGJTZGEtM3U5dEhYeGNNRFVwMHROZm1CdzhVenJlRDA1OFNnTHozaThIWVZ1ejlsQzdLOUhHSXpiT2VCR1FDM2d0VDZLd0c3WjZRcDM0RGgwVGhkNWczem9Fb2F4N1Z6bmh3Tjc3a1Qtd1A5MEk3R21YMWxocmdLR2FSdEpRelZpRzEyREhTNUNTVVpR?oc=5","date":"2026-02-24","type":"pipeline","source":"Stocktwits","summary":"Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits","headline":"Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today?","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNdy1lSGJ2RlhKVTF0VThDVGtLX2c5WERFVUItWGJSQ0VBRE0yaTJ6WjMyMWRnRTlYenItRk5YWm5hWnVXTlVoRlFWTk9weEZzcVlLVXAtbjBWYVFwSGg3NEN1SnBodFU0Yzh4SHMySl9YTWlxam8tZkpDU0gtYnlhdkJkVE1WbFRa?oc=5","date":"2025-10-02","type":"regulatory","source":"Mugglehead Magazine","summary":"Larimar Therapeutics shares jump on positive FDA guidance - Mugglehead Magazine","headline":"Larimar Therapeutics shares jump on positive FDA guidance","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-23","type":"pipeline","source":"simplywall.st","summary":"Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds owners - simplywall.st","headline":"Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds own","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPX1FtZG1rLWRQd20tOXZfUDdCUWVyeWoyWFd6c1VlUklEZjBzUDhkRUtaSzUyemtHUjRQU1FvempFcVFJZ3dzeU43VnA0dW5VSlpSVlhqeV9FYXRqZk9GUDZkOTBqcmlWN3RHQWplNTloM2s2MEJ1TENOSlR1UldiSktxWmo5UDEwdlpLQWxOT0xyX2pXWFh0bFhjWDl4dGJhanEzM1d0NnZXbkVaLUhIaERKbmw4ZmN4NDltc0FQbm5Ob1k1Mk11cmNUNXQteWhISElpdkU5TE55ZGs?oc=5","date":"2025-07-16","type":"deal","source":"The Globe and Mail","summary":"5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail","headline":"5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxPWnFfOWREYThxYkhaWmoyVGZTemlmWlRzMXFHcllFWldMQjY4WldJRDZneUpHTHdpSXlzR1NDREtUcnNFY3h3RGhPdGI1Yi1LWUpvZGtxQzRpRV9McVNkOHlhNC1NT3VFUG1QRjdISTgyV3ZxSXhfMWdzWXFtN1d5eTY1NjU0S3BrVGljMTQxTTFoMWpkNVZRWUZsZlVOSFhyY0hCY09nZzQwREw3SFdrSlJFb2dKLUo5Y0NxdEsxMnlQTHdxajc5SE1mcDIwNHJyUXh2RXdxci1rNXpRWnNpZGNVTm5VZENrRXMyLS1hcTkwUlNnSWpTcURPOF9TMWNBSWF4NXpKUF90U1IxczZQOFFiZ2JCYUpJZkE?oc=5","date":"2025-06-05","type":"pipeline","source":"PR Newswire","summary":"Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight - PR Newswire","headline":"Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Mome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5aSzBGOXhmbzM3VXFqZ041TEk5a005WjZBbDBvSnhDRFBJYkFKYk9sU0lnVkp2XzNkeXU5N2lBSTlmOGp5RXY1WDd4M2VtemdMYk0wX0dlNEJwemhIanBtYk10cHVtcXpMUUVyUTdB?oc=5","date":"2025-04-25","type":"pipeline","source":"PharmaLive","summary":"Elevate Healthcare Marketing: 2025 - PharmaLive","headline":"Elevate Healthcare Marketing: 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPUkhaZ29JYUgyU052ek15d3Q5ODRNM3NleWhlbWhZcUNkUHNZYmh6a3RQTWJnQTlPNk9rVzVDdTNENm96UGxWWW9aVmNfY2xFNFlHb0hkN0xJMWJ6M0ctU1BMNVJFeWxFUW10clZrOFhkRXVZM0NyWmEzRUJranZmbV9TMk1pSDZ3ZUU5TmJHTk52SmF1S3pkWDQxNXg1c1ExMUt0WW9qZGp5RU1W?oc=5","date":"2025-04-04","type":"pipeline","source":"Seeking Alpha","summary":"Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha","headline":"Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":0,"period":"2019-12-31"},{"value":0,"period":"2019-09-30"},{"value":0,"period":"2019-06-30"},{"value":0,"period":"2019-03-31"},{"value":0,"period":"2018-12-31"},{"value":0,"period":"2018-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":154224000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-165673000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":85412000,"cashHistory":[],"totalAssets":145842000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}